Skip to main content
EIDB

Main navigation

  • About Us
    • Our Team
      • Researchers
    • WRAIR
    • HJF
    • Publications
    • Fact Sheets
  • Research
    • Coronaviruses
      • COVID-19
      • MERS
    • Hemorrhagic Fevers
      • Ebola
      • Lassa Fever
      • Marburg
    • Flaviviruses
      • Tick-borne Encephalitis
      • Yellow Fever
      • Zika
  • Global Reach
    • International Network
      • Brazil
      • Europe
      • Ghana
      • Jordan
      • Kenya
      • Liberia
      • Nigeria
      • Puerto Rico
      • Thailand
      • Uganda
      • United States
    • Global Initiatives
      • Joint West Africa Research Group (JWARG)
      • Partnership for Research in the Middle East (PRIME)
  • Community Engagement
    • Community Advisory Board
      • CAB Members
      • CAB Resources
    • Education
    • Events
    • Partners
    • Contact the Community Engagement Team
  • News
  • Careers
  • Search
Marburg virus NIAID

Hemorrhagic Fevers

Marburg

EbolaLassa Fever

Though less well known than Ebola virus, Marburg virus is a filovirus in the same disease family that causes hemorrhagic fever and has a fatality rate of up to 88%. There are currently no approved vaccines or therapeutics to treat individuals infected with the virus.

In 2019 EIDB conducted a Phase 1 trial to evaluate a Marburg vaccine product developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).

The trial, which was conducted at WRAIR’s Clinical Trial Center with 40 healthy adult volunteers, evaluated the safety tolerability and immunogenicity of an investigational recombinant chimpanzee adenovirus Type 3-vectored Marburg virus vaccine.

Sign Up For Our Newsletter

WRAIR Logo
HJF Logo

Social Navigation

  • Facebook
  • Twitter

Footer

  • Accessibility
  • Disclaimers
  • Privacy
  • Contact EIDB

©2022 Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

This site was created by HJF. The appearance of U.S. Department of Defense (DoD) visual information does not imply or constitute DoD endorsement.